455 related articles for article (PubMed ID: 20035588)
1. Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder.
de Jong CG; Van De Voorde S; Roeyers H; Raymaekers R; Allen AJ; Knijff S; Verhelst H; Temmink AH; Smit LM; Rodriques-Pereira R; Vandenberghe D; van Welsen I; ter Schuren L; Al-Hakim M; Amin A; Vlasveld L; Oosterlaan J; Sergeant JA
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):699-707. PubMed ID: 20035588
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
Wietecha L; Williams D; Shaywitz S; Shaywitz B; Hooper SR; Wigal SB; Dunn D; McBurnett K
J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
[TBL] [Abstract][Full Text] [Related]
3. Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial.
Shaywitz S; Shaywitz B; Wietecha L; Wigal S; McBurnett K; Williams D; Kronenberger WG; Hooper SR
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):19-28. PubMed ID: 27410907
[TBL] [Abstract][Full Text] [Related]
4. Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine.
Gau SS; Shang CY
Int J Neuropsychopharmacol; 2010 Mar; 13(2):243-56. PubMed ID: 19849892
[TBL] [Abstract][Full Text] [Related]
5. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
[TBL] [Abstract][Full Text] [Related]
6. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study.
Adler L; Tanaka Y; Williams D; Trzepacz PT; Goto T; Allen AJ; Escobar R; Upadhyaya HP
J Clin Psychopharmacol; 2014 Aug; 34(4):461-6. PubMed ID: 24977716
[TBL] [Abstract][Full Text] [Related]
7. Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder.
Shang CY; Gau SS
J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):353-63. PubMed ID: 23083022
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study.
Maziade M; Rouleau N; Lee B; Rogers A; Davis L; Dickson R
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):709-18. PubMed ID: 20035589
[TBL] [Abstract][Full Text] [Related]
10. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
[TBL] [Abstract][Full Text] [Related]
11. Reading outcomes of children and adolescents with attention-deficit/hyperactivity disorder and dyslexia following atomoxetine treatment.
Shaywitz BA; Williams DW; Fox BK; Wietecha LA
J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):419-25. PubMed ID: 25299355
[TBL] [Abstract][Full Text] [Related]
12. How distinctive are ADHD and RD? Results of a double dissociation study.
de Jong CG; Van De Voorde S; Roeyers H; Raymaekers R; Oosterlaan J; Sergeant JA
J Abnorm Child Psychol; 2009 Oct; 37(7):1007-17. PubMed ID: 19488850
[TBL] [Abstract][Full Text] [Related]
13. Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms.
McBurnett K; Clemow D; Williams D; Villodas M; Wietecha L; Barkley R
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):38-42. PubMed ID: 27845858
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine effects on executive function as measured by the BRIEF--a in young adults with ADHD: a randomized, double-blind, placebo-controlled study.
Adler LA; Clemow DB; Williams DW; Durell TM
PLoS One; 2014; 9(8):e104175. PubMed ID: 25148243
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
[TBL] [Abstract][Full Text] [Related]
16. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
17. Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder.
Wu CS; Shang CY; Lin HY; Gau SS
J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):187-196. PubMed ID: 33890819
[No Abstract] [Full Text] [Related]
18. The influence of working memory load on response inhibition in children with attention-deficit/hyperactivity disorder or reading disorder.
Van De Voorde S; Roeyers H; Verté S; Wiersema JR
J Clin Exp Neuropsychol; 2011 Aug; 33(7):753-64. PubMed ID: 21432708
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
Chang K; Nayar D; Howe M; Rana M
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
[TBL] [Abstract][Full Text] [Related]
20. Effect of atomoxetine on executive function impairments in adults with ADHD.
Brown TE; Holdnack J; Saylor K; Adler L; Spencer T; Williams DW; Padival AK; Schuh K; Trzepacz PT; Kelsey D
J Atten Disord; 2011 Feb; 15(2):130-8. PubMed ID: 20026871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
